KBI Biopharma BVBA Opens in Leuven, Belgium, Offering Analytical Services to the European Market
KBI Biopharma, Inc. announced today that its subsidiary KBI Biopharma BVBA has begun operations at its newly completed laboratories in Leuven, Belgium. The laboratories are co-located with JSR Life Sciences’ Amsphere™ A3 European manufacturing site and represent KBI’s first service offering based in Europe. KBI Biopharma BVBA initiated its first client-sponsored programs in May 2018.
KBI Biopharma BVBA has capabilities for GMP and non-GMP services including analytical development, formulation development, biopharmaceutical characterization and cGMP quality control testing for release and stability of drug substance and drug product.
“A key strength of this new facility is the utilization of our existing procedures and knowledge base,” said Cale Halbleib, PhD, Director of Biopharmaceutical Development at KBI Biopharma BVBA. “Our Leuven site is a European extension of KBI’s well-established development and GMP testing expertise. We can now leverage those capabilities in both the US and EU including transfer and co-validation of analytical methods for customers.”
“The establishment of our analytical services laboratory in Belgium is a key strategic objective for KBI,” said President and CEO of KBI Biopharma, Inc., Tim Kelly, PhD. “Through this expansion, we are building on our exceptional foundation in analytical sciences to offer an even more comprehensive solution to our client partners who seek to conduct clinical trials and register their products in the EU and US.”
To date, KBI has helped to advance more than 300 molecules in more than 70 unique health indications. By expanding its footprint into Europe, KBI will continue to accelerate an even broader range of drug development programs for its global client base.
About KBI Biopharma, Inc.
KBI Biopharma is a biopharmaceutical Contract Development & Manufacturing Organization driven to accelerate the development of innovative discoveries into life-changing biological products and expand global access of medicines to patients in need.
From early-stage biotech to academic/non-profit organizations to many of the world’s largest pharmaceutical companies, KBI has served 300+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapies for our clients.
KBI was founded in 1996 and operates facilities in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium.
For KBI Biopharma, Inc.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
NIKON-CORPORATION23.1.2019 08:04 | Pressemeddelelse
Nikon, ASML And Carl Zeiss Sign Agreement to Settle All Litigation
PHILIP-MORRIS23.1.2019 08:02 | Pressemeddelelse
PMI Explores Global Public Health Issues in New White Paper
NY-CORSAIR23.1.2019 05:38 | Pressemeddelelse
Corsair Infrastructure Partners Announces Transaction Involving DP World Australia
YOKOGAWA-ELECTRIC23.1.2019 05:02 | Pressemeddelelse
Yokogawa Joins Global 100 Most Sustainable Corporations in the World Index
V-CAT-VIETNAM23.1.2019 01:02 | Pressemeddelelse
V-CAT to Begin a New Type of Crowdfunding, Using Digital Currency
NV-RIMINI-STREET,-INC.23.1.2019 00:02 | Pressemeddelelse
Prominent Trade Consulting Firm in South Korea Switches to Rimini Street Support for Its Oracle Database
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum